ClinicalTrials.Veeva

Menu
A

Austin Research Center for Retina | Austin, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

GT005
Ranibizumab
Aflibercept
KSI-301
Faricimab
CU06-1004
BI 765128
THR-149
BI 764524
ONL1204

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 18 total trials
Locations recently updated

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular de...

Active, not recruiting
Age-Related Macular Degeneration
Nonexudative Age-related Macular Degeneration
Device: i-Lumen(TM) AMD
Device: i-Lumen(TM) AMD Sham

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)
Locations recently updated

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling
Macular Degeneration
Drug: Ranibizumab
Drug: Zifibancimig

Trial sponsors

Roche logo
AbbVie logo
Boehringer Ingelheim logo
G
Jaeb Center for Health Research logo
Kodiak Sciences logo
Bayer logo
C
O
Oxurion logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems